SASL Swiss Cirrhosis Cohort (SSCiCoS)

University Hospital Basel

Status: Enrolling

Conditions: Liver Cirrhosis

Treatments: Other: Data collection

Study type: Observational

Funder types: Other

Identifiers

NCT06092385

2022-01370 bb23Bernsmeier;

Details and patient eligibility

About

This is a national prospective long-term multicentre observational cohort study following patients with cirrhosis in order to systematically and longitudinally record epidemiological, clinical, histological, psychosocial and patient-reported data and biobank biological material from patients with cirrhosis.

The central element of all scientific operation and productivity in the Swiss Cirrhosis Cohort Study (SSCiCoS) is the so-called "nested project" (NP). Based on the evolving large pool of data and biological samples, SSCiCoS investigators use the data pool in order to investigate specific hypotheses and questions.

Full description

For patients with end-stage cirrhosis there are no treatment options other than transplantation, a medically and ethically challenging procedure. The challenge therefore is to prevent the need for liver transplantation in as many patients with cirrhosis as possible.

In order to reach this aim, patients with cirrhosis should be identified and followed regularly according to the highest standard of current knowledge. Numerous aspects of the disease need to be detailed: its epidemiology in Switzerland, its pathophysiology including the mechanism of scar tissue generation and resolution, the associated immune dysfunction and subsequent organ failures, disease related psychosocial and behavioural factors, perceived burden of liver cirrhosis in patients, diagnostic and prognostic biomarkers for disease dynamics, both progression and regression of disease, and stage-specific therapeutic strategies.

This is a national prospective long-term multicentre observational cohort study following patients with cirrhosis in order to systematically and longitudinally record epidemiological, clinical, histological, psychosocial and patient-reported data and biobank biological material from patients with cirrhosis.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• A) Patients with chronic liver disease and histologically proven cirrhosis
• B) Control subjects with no signs of cirrhosis

Exclusion criteria

• Age <18 years
• patients who developed hepatocellular carcinoma (HCC) and/or cholangiocellular carcinoma (CCC)

Trial design

3,000 participants in 2 patient groups

Patients with chronic liver disease and histologically proven cirrhosis

Treatment:

Other: Data collection

Control subjects with no signs of cirrhosis

Treatment:

Other: Data collection